{"filing":{"accession_number":"0001193125-26-357120","cik":"0001810560","ticker":"REVBW","company_name":"REVELATION BIOSCIENCES, INC.","form":"8-K","filing_date":"2026-08-19","report_date":"2026-08-17","primary_document":"revb-20260817.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526357120/revb-20260817.htm"},"events":[{"id":28603,"run_id":26171,"accession_number":"0001193125-26-357120","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The Compensation Committee approved and granted restricted stock awards to the CEO (James Rolke, 208,076 shares) and CFO (Chester S. Zygmont, III, 208,073 shares) effective August 17, 2026, pursuant to the 2021 Equity Incentive Plan. This is a direct disclosure of compensatory arrangements for named executives with specific vesting conditions tied to market capitalization milestones and time-based tranches, which is the core definition of exec_compensation under Item 5.02(e).","company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVBW","filing_date":"2026-08-19","form":"8-K","submitted_at":null,"items":[{"id":30601,"accession_number":"0001193125-26-357120","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Compensation Committee approved and granted restricted stock awards to the CEO (James Rolke, 208,076 shares) and CFO (Chester S. Zygmont, III, 208,073 shares) effective August 17, 2026, pursuant to the 2021 Equity Incentive Plan. This is a direct disclosure of compensatory arrangements for named executives with specific vesting conditions tied to market capitalization milestones and time-based tranches, which is the core definition of exec_compensation under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T21:08:37.213482+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30601,"accession_number":"0001193125-26-357120","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Compensation Committee approved and granted restricted stock awards to the CEO (James Rolke, 208,076 shares) and CFO (Chester S. Zygmont, III, 208,073 shares) effective August 17, 2026, pursuant to the 2021 Equity Incentive Plan. This is a direct disclosure of compensatory arrangements for named executives with specific vesting conditions tied to market capitalization milestones and time-based tranches, which is the core definition of exec_compensation under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T21:08:37.213482+00:00","company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVBW","filing_date":"2026-08-19"}]}